Virus-like Particle Vaccines: A Prospective Panacea Against an Avian Influenza Panzootic Show others and affiliations
2020 (English) In: Vaccines, E-ISSN 2076-393X, Vol. 8, no 4, article id 694Article, book review (Refereed) Published
Abstract [en]
Epizootics of highly pathogenic avian influenza (HPAI) have resulted in the deaths of millions of birds leading to huge financial losses to the poultry industry worldwide. The roles of migratory wild birds in the harbouring, mutation, and transmission of avian influenza viruses (AIVs), and the lack of broad-spectrum prophylactic vaccines present imminent threats of a global panzootic. To prevent this, control measures that include effective AIV surveillance programmes, treatment regimens, and universal vaccines are being developed and analysed for their effectiveness. We reviewed the epidemiology of AIVs with regards to past avian influenza (AI) outbreaks in birds. The AIV surveillance programmes in wild and domestic birds, as well as their roles in AI control were also evaluated. We discussed the limitations of the currently used AI vaccines, which necessitated the development of a universal vaccine. We evaluated the current development of AI vaccines based upon virus-like particles (VLPs), particularly those displaying the matrix-2 ectodomain (M2e) peptide. Finally, we highlighted the prospects of these VLP vaccines as universal vaccines with the potential of preventing an AI panzootic
Place, publisher, year, edition, pages MDPI, 2020. Vol. 8, no 4, article id 694
Keywords [en]
Avian influenza, surveillance, avian influenza vaccine, VLP vaccine, M2e, veterinary avian influenza vaccine, universal influenza vaccines
National Category
Medical Bioscience
Identifiers URN: urn:nbn:se:oru:diva-92841 DOI: 10.3390/vaccines8040694 ISI: 000601757100001 PubMedID: 33227887 Scopus ID: 2-s2.0-85096298337 OAI: oai:DiVA.org:oru-92841 DiVA, id: diva2:1577186
Note Funding Agencies:
GCRF Networks in Vaccines Research and Development UK Research & Innovation (UKRI)
Biotechnology and Biological Sciences Research Council (BBSRC) UK Research & Innovation (UKRI)
Medical Research Council UK (MRC)
IVVN
2021-07-022021-07-022021-07-02 Bibliographically approved